Quality assurance of drugs used in clinical trials: Proposal for adapting guidelines

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Newton, Paul N ^a   Schellenberg, David ^b   Ashley, Elizabeth A ^c   Ravinetto, Raffaella ^d   Green, Michael D ^e   Ter Kuile, Feiko O ^f   Tabernero, Patricia ^g   White, Nicholas J ^g   Guerin, Philippe J ^g  

^a MAHOSOT HOSPITAL   (Laos)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; COUNTERFEIT DRUG; DRUG;

ARTICLE; CLINICAL RESEARCH; DEVELOPING COUNTRY; DRUG CONTROL; DRUG EFFICACY; DRUG QUALITY; DRUG USE; HUMAN; MEDICAL SERVICE; MEDICAL SOCIETY; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY CONTROL; CLINICAL TRIAL (TOPIC); DEVICES; STANDARDS;

CLINICAL TRIALS AS TOPIC; COUNTERFEIT DRUGS; EQUIPMENT AND SUPPLIES; GUIDELINES AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; PLACEBOS;

EID: 84929380151     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h602     Document Type: Article

References (28)

1. Mori M, Ravinetto R, Jacobs J. Quality of medical devices and in vitro diagnostics in resource-limited settings. Trop Med Int Health 2011;16:1439-49.
2. Newton PN, Green MD, Fernández FM, Day N.P., White NJ Counterfeit anti-infective medicines. Lancet Infect Dis 2006;6:602-13.
3. World Health Organization. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series No. 850, 1995, Annex 3. http://apps.who.int/medicinedocs/pdf/whozip13e/whozip13e.pdf.
4. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline. Guideline for good clinical practice E6(R1). 1996. www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf.
5. Lang T, Cheah PY, White NJ Clinical research: time for sensible global guidelines. Lancet 2011;377:1553-5.
6. Caudron JM, Ford N, Henkens M., Macé C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008;13:1062-72.
7. Newton PN, Amin AA, Bird C, Passmore P., Dukes G, Tomson G, et al The primacy of public health considerations in defining poor quality medicines. PLoS Med 2011;8:e1001139.
8. Idindili B, Masanja H, Urassa H., Bunini W, van Jaarsveld P, Aponte JJ, et al Randomized controlled safety and efficacy trial of 2 vitamin A supplementation schedules in Tanzanian infants. Am J Clin Nutr 2007;85:1312-9.
9. World Health Organization. Assessment of medicines regulatory systems in sub-Saharan African countries. An overview of findings from 26 assessment reports. 2010. http://apps.who.int/medicinedocs/en/d/Js17577en/.
10. Strauch S, Jantratid E, Dressman J.B., Junginger HE, Kopp S, Midha KK, et al Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride. J Pharm Sci2011;100:11-21.
11. Weidekamm E, Rüsing G, Caplain H., Sörgel F, Crevoisier C. Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 1998;54:615-19.
12. Shaw TR. Trade names or approved names. Part III. Special cases. The digoxin affair. Postgrad Med J 1974;50:98-102.
13. Gutman J, Green MD, Durand S, Rojas O.V., Ganguly B., Quezada WM, et al Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria. Malar J 2009;8:58.
14. Sowunmi A, Salako LA, Ogunbona FA Bioavailability of sulphate and dihydrochloride salts of quinine. Afr J Med Med Sci 1994;23:275-8.
15. Medicines and Healthcare Products Regulatory Agency. Press release: four month trial concludes of Operation Singapore - the most serious known breach of counterfeit medicine in the regulated supply chain. April 2011. www.mhra.gov.uk/NewsCentre/Pressreleases/CON114481.
16. Riveros C, Dechartres A, Perrodeau E., Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med 2013;10:e1001566.
17. Golomb BA, Erickson LC, Koperski S, Sack D., Enkin M, Howick J. What's in placebos: who knows? Analysis of randomized, controlled trials. Ann Intern Med 2010;153:532-5.
18. Csillag C. Epidemic of counterfeit drugs causes concern in Brazil. Lancet 1998;352:553.
19. Bossuyt PM, Reitsma JB, Bruns D.E., Gatsonis CA, Glasziou PP, Irwig LM, et al Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4.
20. Hoffmann TC, Glasziou PP, Boutron I, Milne R., Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687.
21. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ2013;346:e7586.
22. CONSORT. Transparent reporting of trials. www.consort-statement.org/.
23. Standard Protocol Items: Recommendations for Interventional Trials. SPIRIT statement. www.spirit-statement.org/.
24. Standards for the Reporting of Diagnostic Accuracy Studies. STARD Statement. www.stard-statement.org/.
25. Equator Network. Better reporting of interventions: template for intervention description and replications (TIDieR) checklist and guide. www.equator-network.org/reporting-guidelines/tidier/.
26. The Global Fund to Fight AIDS, Tuberculosis and Malaria. List of countries considered as stringent regulatory authorities (SRA)from 1st July 2009. www.theglobalfund.org/documents/psm/PSM-CountriesSRA-List-en/D.
27. Altman DG, Royston JP The hidden effect of time. Stat Med 1988;7:629-37.
28. World Health Organization. WHO project for the surveillance and monitoring of SSFFC medical products. 2013 http://apps.who.int/medicinedocs/documents/s20287en/s20287en.pdf.